| Followers | 832 |
| Posts | 119978 |
| Boards Moderated | 17 |
| Alias Born | 09/05/2002 |
Thursday, January 11, 2007 11:53:01 PM
>Would they price it purely on revenue maximization vs the clear indications, or cheaper to try to expand its scope of application?<
The latter, according to GTC’s own guidance.
The big underserved market is prophylactic use by hemophiliacs, where obtaining reimbursement would necessitate a substantially lower price than what NovoSeven sells for.
>Care to conjecture what they might ask for it?<
I'll get back to you on that one
The latter, according to GTC’s own guidance.
The big underserved market is prophylactic use by hemophiliacs, where obtaining reimbursement would necessitate a substantially lower price than what NovoSeven sells for.
>Care to conjecture what they might ask for it?<
I'll get back to you on that one
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
